In addition, the CANTOS trial [33] revealed that suppression of inflammation by canakinumab, the IL-1β antibody, resulted in a 15% reduction of cardiovascular end points in patients with established atherosclerosis. The gene discussed is IL1B; the disease is atherosclerosis.